6CM
XERS icon

683 Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

683 Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-121,367
Closed -$311K – 330
2022
Q1 		$311K Hold
121,367
– – 0.02% 231
2021
Q4 		$356K Buy
121,367
+91,367
+305% +$197K 0.01% 248
2021
Q3 		$74K Buy
+30,000
New +$87.1K ﹤0.01% 197
2021
Q1 		– Sell
-178,200
Closed -$877K – 240
2020
Q4 		$877K Sell
178,200
-55,400
-24% -$277K 0.04% 124
2020
Q3 		$1.39M Buy
+233,600
New +$934K 0.1% 92

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

683 Capital Management's XERS Position: Q2 2022 in Review

683 Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 121,367 shares — an estimated $311K sold.

683 Capital Management first reported a position in XERS in Q3 2020 and held it in 5 quarters. The position peaked at $1.39M in Q3 2020. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

  • 683 Capital Management reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
  • 683 Capital Management sold 121,367 Xeris Biopharma Holdings shares in Q2 2022, an estimated $311K.
  • 683 Capital Management first reported a position in Xeris Biopharma Holdings in Q3 2020 and held it in 5 quarters.
  • 683 Capital Management's Xeris Biopharma Holdings position peaked at $1.39M in Q3 2020.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.